RXL-1SM 5mg Peptide | Third-Party Tested | RemedyX Labs
Order RXL-1SM 5mg research peptide online from RemedyX Labs. Verified batch COAs confirm purity and identity. Secure checkout, competitive pricing, and fast shipping.
RXL-1SM is a synthetic research peptide supplied as a lyophilized powder. It is used in controlled laboratory studies of metabolic signaling pathways and receptor-binding research models. Every batch is independently tested by a third-party laboratory to confirm identity and purity, with batch-specific Certificates of Analysis (COA) available for full transparency. For laboratory research use only. Not for human or animal use. Not intended for diagnostic, therapeutic, clinical, or commercial use.
- Price: 35.00 USD
- In stock
- Purity: 99%+
- CAS Number: 910463-68-2
- Molecular Formula: C187H291N45O59
- Molecular Weight: 4114
- Specification: 5mg/vial
- Contents: Lyophilized Powder
- Appearance: White to Off-White
- Intended Use: Research Only
- SKU: RXL-SKU-0028
Cited Research
Spotlight on the Mechanism of Action of Semaglutide
This study examines the biological mechanisms underlying the pharmacological activity of semaglutide.
PMC, 2024
Semaglutide for the Treatment of Obesity
Researchers investigated the use of semaglutide as a therapeutic intervention for the management of obesity.
PubMed, 2022
Unraveling the Safety Profile of GLP-1 Receptor Agonists
This investigation analyzes the safety profile and physiological effects associated with GLP-1 receptor agonist compounds.
PubMed
Pharmacokinetics, Safety and Tolerability of Once-Weekly Subcutaneous Semaglutide in Healthy Chinese Subjects: A Double-Blind, Phase 1, Randomized Controlled Trial
This phase 1 trial characterizes the pharmacokinetics and tolerability profile of weekly subcutaneous semaglutide in healthy Chinese participants.
PubMed, 2020
A Placebo-Controlled Trial of Subcutaneous Semaglutide in Nonalcoholic Steatohepatitis
This placebo-controlled study investigates the impact of subcutaneous semaglutide on nonalcoholic steatohepatitis and associated liver fibrosis.
PubMed, 2020
Effects of semaglutide on beta cell function and glycaemic control in participants with type 2 diabetes: a randomised, double-blind, placebo-controlled trial
This randomized trial investigates how semaglutide influences beta cell function and glycemic control in individuals diagnosed with type 2 diabetes.
PubMed, 2017
Population Pharmacokinetics of Semaglutide for Type 2 Diabetes
This study develops a population pharmacokinetic model to describe the behavior of semaglutide in patients with type 2 diabetes.
PubMed, 2019
Semaglutide in Patients with Heart Failure with Preserved Ejection Fraction and Obesity
This study explores the effects of semaglutide in patients living with obesity and heart failure with preserved ejection fraction.
PubMed, 2023
Effect of Weekly Subcutaneous Semaglutide vs Daily Liraglutide on Body Weight in Adults With Overweight or Obesity Without Diabetes: The STEP 8 Randomized Clinical Trial
This trial compares the effects of weekly subcutaneous semaglutide versus daily liraglutide on body weight reduction in adults with overweight or obesity.
PubMed, 2022
12-month neurological and psychiatric outcomes of semaglutide use for type 2 diabetes: a propensity-score matched cohort study
This cohort study analyzes neurological and psychiatric outcomes in patients with type 2 diabetes following 12 months of semaglutide use.
PubMed, 2025
Long-term weight loss effects of semaglutide in obesity without diabetes in the SELECT trial
Reports sustained weight loss over long follow-up in the SELECT trial population.
PubMed, 2024
Weight Loss Outcomes Associated With Semaglutide Treatment for Patients With Overweight or Obesity
Reports real-world weight changes over three and six months.
PubMed, 2022
A Systematic Review and Meta-Analysis of Randomized Trials of Semaglutide for Weight Loss
Finds clinically meaningful sustained weight loss across randomized trials.
PubMed, 2024
Two-year effects of semaglutide in adults with overweight or obesity: STEP 5
Reports sustained weight loss through 104 weeks versus placebo.
PubMed, 2022
Once-weekly semaglutide 7.2 mg in adults with obesity
Evaluates a higher semaglutide dose in obesity treatment.
PubMed, 2025
Semaglutide use in people with obesity and type 2 diabetes: real-world outcomes
Reports real-world changes in weight, BMI and HbA1c.
PubMed, 2024
Semaglutide 2.4 mg Clinical Outcomes in Patients with Obesity or Overweight
Reports weight outcomes in routine clinical practice.
PubMed, 2025
Semaglutide: Double-edged Sword with Risks and Benefits
Reviews efficacy alongside adverse-effect and monitoring considerations.
PMC, 2025